The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.本發明係關於針對EGFR/ErbB/HER家族內之受體之改良之治療劑,其更廣泛地干擾HER家族之多個成員(泛-HER抑制)。更特定言之,本發明係關於抗體組成物用於人類癌症療法之用途。試管內研究已顯示靶向多個HER家族受體之本發明抗體組成物優於僅靶向一種HER家族受體之抗體組成物。
